Search results for "treatment strategies"

showing 4 items of 4 documents

Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease St…

2022

Correction to Lancet Gastroenterol Hepatol 2022; 7: 627-47. Lancet Gastroenterol Hepatol. 2022 Aug;7(8):704. doi: 10.1016/S2468-1253(22)00210-2. PMID: 35809605. Background: Colorectal cancer is the third leading cause of cancer deaths worldwide. Given the recent increasing trends in colorectal cancer incidence globally, up-to-date information on the colorectal cancer burden could guide screening, early detection, and treatment strategies, and help effectively allocate resources. We examined the temporal patterns of the global, regional, and national burden of colorectal cancer and its risk factors in 204 countries and territories across the past three decades. Methods: Estimates of incidenc…

AdultMED/42 - IGIENE GENERALE E APPLICATAIMPACTcolorectal cancerColorectal NeoplasmGBD 2019 Colorectal Cancer CollaboratorsHEREDITARYGlobal Burden of DiseaseCancer screeningDISPARITIESSDG 3 - Good Health and Well-beingCancer treatment strategiesRisk FactorsQuality-Adjusted Life YearCOLONGlobal studiesDALY GBD colorectal cancerrisk factorsHumansGlobal Burden of Disease StudyEarly Detection of CancerHepatologyMORTALITYGastroenterologyCancer incidence ratesMiddle AgedCancer burdenSURVIVAL/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSEXGENDERQuality-Adjusted Life YearsColorectal NeoplasmsHumanThe Lancet Gastroenterology & Hepatology
researchProduct

Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?

2014

Introduction: Treatment of ovarian cancer has been long standardized with the inclusion of surgery and chemotherapy based on platinum and taxanes, this strategy reaching high remission rates. However, when this treatment fails, further options are available with little benefit. Since ovarian cancer has specific immunologic features, actually immunotherapy is under evalua- 15 tion to overcome treatment failure in patients experiencing recurrence. Areas covered: Immunogenicity of ovarian cancer and its relationship with clinical outcomes is briefly reviewed. The kinds of immunotherapeutic strategies are summarized. The clinical trials investigating immunotherapy in recurrent ovarian cancer pa…

Oncologymedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryTreatment failureInternal medicineDrug DiscoverymedicineAnimalsHumansIn patientTreatment FailureBiologyOvarian Neoplasmsantibody cancer vaccines cell transfer immune system immunotherapy ovarian cancer recurrence treatment strategiesPharmacologyChemotherapybusiness.industryTreatment optionsImmunotherapymedicine.diseaseClinical trialRecurrent Ovarian CancerImmunologyFemaleImmunotherapyHuman medicineNeoplasm Recurrence LocalOvarian cancerbusinessEngineering sciences. TechnologyExpert Opinion on Biological Therapy
researchProduct

Editorial: Environmental enrichment as a treatment? Epigenetic mechanisms, challenges and limitations

2021

PharmacologyEnvironmental enrichmentbusiness.industrytranslationalagingRM1-950Computational biologyDNAenvironmental enrichment (EE)aging; DNA; environmental enrichment (EE); epigenetic; translational; treatment strategiestreatment strategiesMedicineTreatment strategyPharmacology (medical)Therapeutics. PharmacologyEpigeneticsbusinessepigenetic
researchProduct

Treatment strategies and outcome of the exstrophy–epispadias complex in germany: data from the german CURE-Net

2020

Introduction: To evaluate the impact of reconstructive strategies and post-operative management on short- and long-term surgical outcome and complications of classical bladder exstrophy (CBE) patients' comprehensive data of the multicenter German-wide Network for Congenital Uro-Rectal malformations (CURE-Net) were analyzed. Methods: Descriptive analyses were performed between 34 prospectively collected CBE patients born since 2009, median 3 months old [interquartile range (IQR), 2–4 months], and 113 cross-sectional patients, median 12 years old (IQR, 6–21 years). Results: The majority of included individuals were males (67%). Sixty-eight percent of the prospectively observed and 53% of the …

medicine.medical_specialtypost-operative complicationsTherapieerfolgUrinary systemstaged approachRenal functionEpispadias030204 cardiovascular system & hematologyPediatricsBlasenekstrophie03 medical and health sciences0302 clinical medicineInterquartile rangeMedizinische Fakultät030225 pediatricstreatment strategiesmedicineKomplikationddc:610Treatment outcomePostoperative Phaseoutcome assessmentOriginal ResearchUpper urinary tractbusiness.industrylcsh:RJ1-570lcsh:PediatricsBladder exstrophy; Surgerysingle-stage approachmedicine.diseaseSurgeryBladder exstrophyInguinal herniaexstrophy–epispadias complex (EEC)Pediatrics Perinatology and Child HealthTreatment strategyoperative outcomebusinessDDC 610 / Medicine & health
researchProduct